PRKN and ovarian carcinoma: In cancer, although the association between the exact alterations of PARK2 and cancer susceptibility is not well understood, the mutations, deletion, copy number alterations, promoter hypermethylation, and aberrant mRNA and protein expression of PARK2 have all been found to be prevalent across human malignancies, especially glioma, lung, breast, colon, and ovarian cancer [7, 67–70].